Journal
CELL
Volume 149, Issue 2, Pages 274-293Publisher
CELL PRESS
DOI: 10.1016/j.cell.2012.03.017
Keywords
-
Categories
Funding
- National Institutes of Health
- Howard Hughes Medical Institute
- Department of Defense
- Keck Foundation
- Whitehead Institute
- Canadian Institutes of Health Research
- Les Fonds de la Recherche en Sante du Quebec
Ask authors/readers for more resources
The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis. The pathway regulates many major cellular processes and is implicated in an increasing number of pathological conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration. Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging. We further discuss pharmacological approaches to treat human pathologies linked to mTOR deregulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available